895 reports of this reaction
1.9% of all OXAZEPAM reports
#8 most reported adverse reaction
SOMNOLENCE is the #8 most commonly reported adverse reaction for OXAZEPAM, manufactured by Actavis Pharma, Inc.. There are 895 FDA adverse event reports linking OXAZEPAM to SOMNOLENCE. This represents approximately 1.9% of all 46,840 adverse event reports for this drug.
Patients taking OXAZEPAM who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for OXAZEPAM, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for OXAZEPAM:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 895 FDA reports for OXAZEPAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 1.9% of all adverse event reports for OXAZEPAM, making it a notable side effect.
If you experience somnolence while taking OXAZEPAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.